GLPG Galapagos Corp: Enterprise Value to EBITDA Ratio
Maintaining the Galapagos NV customer base is hindered by the loss of exclusivity for legacy drugs prior to the release of new developments. Comparing the business's EV/EBITDA multiple history on GURU.Markets, we see that the 0.00 metric determines the status of the valuation parameter. The company's success relies on regulatory approvals and partnerships with pharma industry behemoths, while its intellectual potential is supported by a strong academic foundation of European scientists.
Comprehensive metric breakdowns and analytics for glpg.com (GLPG)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
GLPG - Net Profit|Expected Profit Galapagos NV|GLPG - Market Cap to Net Income|Forward P/E Multiple Galapagos NV|GLPG - PEG Multiple|EV/EBITDA Multiple Galapagos Corp|GLPG - Operating profit before depreciation charges|Earnings per share for the last twelve months Galapagos|GLPG - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months glpg.com|GLPG - Expected net earnings per share growth this year|Expected earnings per share growth for next year Galapagos NV
Basic company analysis:Galapagos Genomics GLPG
A conservative investor utilizes the EV/EBITDA multiple to determine the real value of a business, comparing the total value of capital and debt against operating profit before taxes and interest. For Galapagos NV (GLPG), this indicator confirms the resilience of a model where licensing royalties and partnerships with pharma behemoths generate a cash flow capable of efficiently servicing the company's debt load.
Competitors of Galapagos NV
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|ANIP (anipharmaceuticals.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple MNKD (MannKind)|Enterprise Value to EBITDA Multiple Amphastar Pharmaceuticals Inc|Pacira - EV/EBITDA Multiple|SPRY - EV/EBITDA Multiple|Theravance Biopharma (TBPH) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AQST (aquestive.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SCPH (scPharmaceuticals, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Tectonic|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tonix Pharmaceuticals Inc. (TNXP)|SXTC: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple EPRX (Eupraxia Pharmaceuticals Inc.)|EV/EBITDA Multiple bioharvest.com BHST|eXoZymes - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Oramed Pharmaceuticals (ORMP)|enterabio.com (ENTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA MindWalk Therapeutics (HYFT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ABVC BioPharma|cumberlandpharma.com (CPIX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio QNTM (Quantum BioPharma)|FGEN (FibroGen Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Telomir Pharma TELO|RANI: Enterprise Value to Operating Income Before Depreciation|SNYR: Enterprise Value to EBITDA Ratio|RLYB: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LEXX: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Pulmatrix Inc PULM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pheton Holdings Limited|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization APM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lyra Therapeutics, Inc. (LYRA)|IBO: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals, Inc.)|Enterprise Value to EBITDA Multiple cbdMD Inc.|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio CYTO|LIPO: EV/EBITDA Multiple|optinose.com - Business Value to Operating Income Before Depreciation|PIRS (Pieris Pharmaceuticals, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Procaps Group|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|QLI (Qilian International Corp) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|TFFP - Enterprise Value to EBITDA Ratio
